LEXICON
No.4 September 6, 2010

Hyoka-ryoyo; healthcare services to be assessed
評価療養
Sentei-ryoyo; selected healthcare services
選定療養
Senshin-iryo; advanced healthcare services provided using unapproved technology but not using any unapproved drugs or medical devices
先進医療
Kohdo-iryo; advanced healthcare services provided using unapproved drugs or medical devices
高度医療

The specific treatment cost program (特定療養費制度) was revised through the amendment of the Health Insurance Law (健康保険法) in October 2006 and “healthcare services to be assessed (評価療養),”which need to be assessed to determine whether they are worth being reimbursed under...

To read the full story

LEXICON

By Eric Persoff

There has been a growing trend of life science manufacturers collaborating with local governments (e.g., at the municipal and prefectural level) in Japan during the past 3-5 years. This trend is observed not only with domestic manufacturers but among foreign…

By Izuru Ando

Shionogi’s COVID-19 pill ensitrelvir failed to clear the second round of review by a key advisory panel on July 20. The session drew a great deal of attention since the drug is the first candidate for the application of Japan’s…

By Reiji Anasako

The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…

Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…

Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…

A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…